You are here
CBT Pharmaceuticals Announces New Leadership Structure to Drive Global Expansion
Strengthens Management Team with the Appointment of Yuling Li, PhD as Senior Vice President, Process Development and Manufacturing
PLEASANTON, Calif. and HANGZHOU, China, Aug. 16, 2018 (GLOBE NEWSWIRE) -- CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced a new global leadership structure and the appointment of Yuling Li, PhD as Senior Vice President, Process Development and Manufacturing.
Earlier this year, Zhejiang CrownMab Biotech Co. Ltd. was established as a subsidiary of CBT in Hangzhou, Zhejiang, China, to develop combination oncology treatments for the China market and to work closely with our China partners. The Company has also gained significant support from the Zhejiang government toward expansion of CBT’s footprint in Hangzhou. To spearhead CBT’s international growth, Jonathan Wang, PhD, has become Global Chairman, Guo-Liang Yu, PhD, has assumed the role of Global Chief Executive Officer, and Sanjeev Redkar, PhD retains his role as Global President.
“With our U.S. headquarters and subsidiaries in China and Australia, we have expanded our global footprint as we seek to offer cutting-edge clinical trials and treatment regimens for cancer patients worldwide,” stated Guo-Liang Yu, PhD, Global Chief Executive Officer. “We are committed to building a state of the art manufacturing capability in China to supply antibodies globally that Dr. Li will oversee. With over 25 years of biopharmaceutical development experience and an outstanding pedigree, she is a tremendous addition to our organization.”
“Dr. Li has a proven track record advancing assets from early clinical stage through regulatory approval and ultimately to commercialization. Her scientific and organizational leadership skills are a perfect fit as we expand our international presence and clinical trial portfolio,” added Sanjeev Redkar, PhD, President and Chief Executive Officer, CBT Pharmaceuticals.
Dr. Li will be responsible for the manufacturing and supply of CBT’s global products and will oversee building of the manufacturing facility in Hangzhou, China. Dr. Li joins CBT from MedImmune/Astra Zeneca where she spent almost 10 years as a Research and Development Director and Fellow in BioPharmaceutical Development. In that role, she served as chemistry, manufacturing and controls (CMC) team leader and provided strategic and scientific leadership across numerous biopharmaceutical process development and CMC activities. Previously, she spent 15 years at Human Genome Sciences, Inc. (now GlaxoSmithKline) with increasing roles and responsibilities. Dr. Li has been involved in four approved products, more than twenty development programs, has over forty publications, and is the primary inventor for seven issued patents. Dr. Li also has extensive exposure in the biopharmaceutical manufacturing industry as a recipient of multiple awards and as a member of several professional organizations. Dr. Li earned her PhD of Biochemistry and Molecular Biology and her MSc of Biochemistry and Molecular Biology from the Robert Wood Johnson Medical School – Rutgers University, Piscataway, New Jersey. She received her MSc of Biochemistry and BSc of Biological Science from Sun Yatsen (Zhongshan) University, Guangzhou, P. R. China.
“CBT has made meaningful progress over the past two years, and I am honored to join this team focused on developing novel treatment options for cancer patients. This is an exciting time for the Company and I look forward to supporting the pipeline development and growing our capabilities in China,” added Yuling Li, PhD.
About CBT Pharmaceuticals
CBT Pharmaceuticals, Inc. is an innovative biopharmaceutical company committed to becoming a global leader in the discovery and development of oncology combination therapies that harness the immune system and target specific molecular pathways to tame cancer. The company’s existing pipeline consists of five development-stage assets including three novel, humanized monoclonal antibodies that restore the body’s immune system to recognize and kill cancer cells, and two targeted therapies against uncontrolled growth signaling pathways. For more information, please visit www.cbtpharma.com and follow us on Twitter @CBTpharma.